SAN JUAN CAPISTRANO, Calif., April 17, 2007 (PRIME NEWSWIRE) -- American Mold Guard, Inc. (Nasdaq:AMGI) through its wholly owned subsidiary, AMG Scientific, LLC, announced today that it is partnering with Dr. Anthony D. Harris and Dr. Eli N. Perencevich to design a study to evaluate the effectiveness of AMG Scientific's infection control antimicrobial treatment for use in hospitals. The study will look at how well the product eliminates microbes on surfaces and reduces the risk of spreading infection.
Dr. Harris and Dr. Perencevich are associate professors at the University of Maryland School of Medicine in Baltimore, Maryland. Both are practicing infectious disease physicians in the Division of Healthcare Outcomes Research in the Department of Epidemiology and Preventive Medicine at the University of Maryland School of Medicine. They have extensive backgrounds in infectious diseases and have authored numerous publications and medical journal articles on hospital infections.
The clinical study that Dr. Harris and Dr. Perencevich are designing on behalf of AMG Scientific, LLC is intended to be conducted at a major tertiary care hospital in the United States.
"We are pleased to be working with AMG Scientific in the fight against hospital-acquired infections," Dr. Perencevich said. "We believe that AMG Scientific's antimicrobial surface treatment service could have a meaningful impact toward the reduction of surface-transmitted microbes in a hospital environment," said Dr. Harris.
"We are excited to partner with such reputable physicians as Dr. Harris and Dr. Perencevich," said Robert Bayer, Corporate Vice President of Sales for AMG Scientific. "We anticipate that a successful outcome from the completion of these studies will provide the scientific basis needed to market and sell our infection control service to major medical facilities across the country," said Dr. Atif Malik, Chief Science Officer for AMG Scientific.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company's financial position, results of operations, market position, product and service development and market strategy. These statements may be identified by the fact that they use words or phrases such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "will likely result," "will continue," "may," "could" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, competitive product and service development, future broad market acceptance of antimicrobial surface treatment services, difficulties in raising additional capital in the future, difficulties and delays in establishing the "Mold Guard" brand, the impact of the absence of significant proprietary technology underlying our services, changes in the anticipated size or trends of the markets in which we compete, judicial decisions and governmental laws and regulations, and changes in general economic conditions in the markets in which we may compete. For further details and a discussion of these and other risks and uncertainties, see our periodic reports including current reports on Form 8-K, quarterly reports on Form 10-Q and our annual report on Form 10-KSB, furnished to and filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
About American Mold Guard and AMG Scientific, LLC
American Mold Guard, Inc. (Nasdaq:AMGI), founded in 2002, is the industry leader in the field of surface treatment services. AMG Scientific, LLC is a wholly owned subsidiary of AMGI. Established in October 2006. AMG Scientific, LLC is focused on providing long-term antimicrobial infection control on surfaces to health care facilities and large institutions in an effort to provide an additional intervention safety net in the fight against hospital-acquired infections. Visit: www.amgscientific.com or www.americanmoldguard.com.
The American Mold Guard Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2964